CYTOO

CYTOO is a biotechnology firm focused on advancing muscle pathology research and drug discovery through its innovative MyoScreen platform, providing essential tools for modeling muscle diseases and identifying therapeutic targets. CYTOO, headquartered in Grenoble, France, specializes in delivering advanced solutions for muscle pathology research. The company was founded by Matthieu Piel and has undergone strategic pivots to enhance its offerings. The latest funding round, a Series C in November 2011, raised EUR 3.

5 million with Entrepreneurs Fund Management leading the investment alongside Auriga Partners. Total funds raised amount to EUR 3. 5 million, with a current valuation of EUR 16. 123 million.

CYTOO specializes in advanced muscle pathology research and drug discovery solutions through its MyoScreen platform. This unique, integrated system enables the modeling of muscle diseases, identification of therapeutic targets, and validation of compounds, ultimately facilitating accelerated drug development processes. The core offerings include disease modeling, target identification and validation, hit identification and confirmation, lead profiling, and functional potency assays for batch release. These products aim to address genetic, metabolic, and neuromuscular disorders, providing significant insights for pharmaceutical companies and research institutions.

The clientele primarily consists of biopharmaceutical firms and academic researchers engaged in muscle pathology, with the MyoScreen platform being utilized in various markets including North America, Europe, and Asia. CYTOO generates revenue through a structured model that includes partnerships and direct transactions with clients in the pharmaceutical and biotechnology sectors. In 2021, the company reported revenue of EUR 5,409,948 and an EBITDA of EUR 2,274,414. The flagship offerings, such as the MyoScreen platform and associated products like CYTOOchips and CYTOOplates, are integral to the drug discovery process and are sold on a project basis or via subscription agreements.

Clients typically engage with CYTOO for specific research projects that require muscle disease modeling and therapeutic validation, leading to tailored service agreements that establish pricing structures based on the scope and complexity of the services provided. Looking ahead, CYTOO plans to leverage its recent Series C funding of EUR 3. 5 million, secured in November 2011, to enhance its MyoScreen platform and develop new products aimed at expanding its market reach. The company is targeting entry into new geographical regions including Asia and North America by 2023.

These initiatives will be supported by investments in product development and marketing strategies to increase visibility and accessibility of their offerings in the competitive biotechnology landscape.